SHINGRIX

GlaxoSmithKline Inc🇨🇦 Health Canada

Approval Id: 12de86f47999543b
Drug Approval Canada Name: SHINGRIX
Product Name: SHINGRIX
Status: Marketed
Status Date: 2018-01-02
Original Market Date: 2018-01-02
Din: 02468425
Drug Class: Human
Dosage Form: Suspension
Route Of Administration: Intramuscular
Schedule: Schedule D
Ahfs: 80:12.00
Atc Original: J07BK VARICELLA ZOSTER VACCINES
Atc Name: j 07 bk
Aig Number: 0159510001
Company Name: GlaxoSmithKline Inc
Company Address: 800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path: /organization/glaxosmithkline-inc

VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN

50 MCG / 0.5 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

12de86f47999543b

Type

Standard